Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Immunology
Impact-faktor: 1.404 5-jähriger Impact-Faktor: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472

Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.190
11 pages

Quantitating Therapeutically Relevant T-Cell Responses to Cancer Vaccines

Amy C. Hobeika
Department of Surgery, Duke University Medical Center
Timothy M. Clay
Department of Surgery, Duke University Medical Center
Paul J. Mosca
Departments of Surgery, Duke University Medical Center
H. Kim Lyerly
Departments of Surgery, Pathology, and Immunology, Duke University Medical Center
Michael A. Morse
Department of 2Medicine, Duke University Medical Center


Successful application of active immunotherapy to the treatment of cancer will require stimulation of potent antigen-specific T-cell responses. It is not known how numerous or how potent these T cells must be in order to abrogate tumors, but the levels of immunity needed to control chronic viral infections may provide estimates for comparison. Evaluation of the efficacy of a vaccine strategy in attaining these levels of immunity will depend on the use of assays that create a picture of T-cell number and function that correlates with clinical outcomes. We discuss the currently available in vivo and in vitro T-cell assays and their relevance for detecting therapeutic levels of T-cell activity. We also propose a strategy for efficiently evaluating the immunologic efficacy of cancer vaccines so that the most promising candidates can be brought more rapidly into definitive clinical trials.

Articles with similar content:

Immune Complex Analysis in Active Lyme Disease
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 3-4
P. K. Coyle, Steven E. Schutzer
Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options
Critical Reviews™ in Immunology, Vol.40, 2020, issue 1
Xue Yang, Yi-Ping Mou, Ying-Yu Ma, Jia-Yu Yao, Wei-Wei Jin, Mao-Hua Cai, Luo-Qin Fu
Clinical Translation of Peptide-Based Vaccine Trials: The HER-2/neu Model
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Keith L. Knutson, Douglas G. McNeel, Mary L. Disis, Donna Davis, Kathy Schiffman
On the Origin of Cancer Metastasis
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 1-2
Thomas N. Seyfried, Leanne C. Huysentruyt
Optimization of Immunotherapy in Elderly Cancer Patients
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 6
Kei Tomihara, Tyler J. Curiel, Bin Zhang